FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1322-1323 March 23, 2006 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

To the Editor: With regard to the letter by Dr. April (Oct. 6 issue),¹ in reference to a Perspective article by Topol on the overuse of nesiritide for congestive heart failure (July 14 issue)²: Dr. April claims that the current president of the American College of Rheumatology (ACR), along with an unnamed past president, encouraged the use of intravenous office infusion of infliximab (Remicade) over other treatments, such as self-injected medications, "as a way to offset poor reimbursement for patient care." We are writing to respond to Dr. April's unfounded statements.

The issue of access to medications for the . . . [Full Text of this Article]

Related Letters:

Nesiritide — Not Verified
Sackner-Bernstein J., Aaronson K. D., Schreiner G., April P. A., Topol E. J.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:1525-1527, Oct 6, 2005. Correspondence

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.